Memantina Noridem (Memantine Hydrochloride)

Memantine Hydrochloride is used in the management of neurodegenerative conditions that involve glutamatergic excitotoxicity.

• Alzheimer’s disease (moderate to severe): helps improve cognition, daily functioning and may slow disease progression.

• Memantine Hydrochloride acts as a non‑competitive antagonist at the N‑methyl‑D‑aspartate (NMDA) receptor. By binding to the receptor-associated ion channel with moderate affinity, it blocks excessive calcium influx caused by prolonged glutamate activation, thereby reducing excitotoxic neuronal injury while preserving normal synaptic transmission.

Memantina Noridem may cause a range of adverse reactions.

Common Side Effects

• Dizziness: transient light‑headedness, especially after dose initiation.
• Headache: mild to moderate intensity, often resolves with continued therapy.
• Constipation: reduced bowel movements, manageable with diet or laxatives.
• Fatigue: feeling unusually tired or low energy.
• Nausea: mild stomach upset, may improve over time.

Serious or Rare Side Effects

• Seizures: rare occurrence, requires immediate medical attention.
• Hallucinations or psychosis: visual or auditory disturbances, may need dose adjustment.
• Severe hypertension: sudden increase in blood pressure, monitor regularly.
• Allergic reactions: rash, itching, swelling, or difficulty breathing.
• Liver enzyme elevation: abnormal liver function tests, monitor in hepatic impairment.
• Suicidal thoughts: rare but serious, assess mental health regularly.

When prescribing Memantina Noridem, clinicians should consider several safety aspects.

• Renal impairment: adjust dose in patients with reduced kidney function.
• Hepatic impairment: monitor liver enzymes and consider dose modification.
• Elderly patients: start at low dose and titrate slowly to minimize CNS effects.
• Psychiatric history: observe for emergence or worsening of hallucinations or agitation.
• Pregnancy: safety not established; use only if potential benefit justifies risk.
• Breastfeeding: unknown excretion in milk; weigh benefits against potential infant exposure.
• Store at ambient temperature: keep below 25 °C, retain in original container, protect from moisture and direct sunlight.

Memantina Noridem can interact with other medicines that affect the central nervous system or NMDA pathways.

Major Interactions (Avoid)

• Amantadine: combined use may increase risk of confusion, dizziness, and seizures.
• Ketamine: additive NMDA antagonism can lead to profound CNS depression.

Moderate Interactions (Monitor Closely)

• Dextromethorphan: may enhance CNS side effects such as dizziness and hallucinations.
• Anticholinergic agents: can exacerbate cognitive impairment.
• High‑dose vitamin D: may increase serum calcium, potentially affecting neuronal excitability.
• Antihypertensive drugs: monitor blood pressure as memantine can cause hypertension.
• Other NMDA antagonists: assess cumulative effect on glutamate signaling.